Why quantitation is the hard part, not detection

Why quantitation is the hard part, not detection I have a specific reason for asking rather than idle curiosity, and the context is below.

Posting the method first, because I know what the first three replies will otherwise be.

• Column: C18, 4.6 x 250 mm, 5 um
• Mobile phase: 0.1% TFA in water / 0.1% TFA in acetonitrile
• Gradient: 10% to 52% organic over 18 minutes
• Detection: 214 nm
• Injection: 16 uL
• Sample: retatrutide, reconstituted to 2.0 mg/mL, injected within an hour

The main peak integrates at 99% of total area. There is a small feature on the trailing edge that I cannot decide is a shoulder or a baseline artefact, and that is what I am actually asking about.

the opening post is right about the mechanism and I think understates the practical bit.

Precision of home tests: most consumer-accessible devices are not precise to the level people want ("is this 99% pure or 97% pure"). They give a yes/no or a rough category, not a quantitative number.

Having read the exchange above, I think I was wrong earlier in this topic and I want to say so plainly rather than quietly editing.

The correction was fair and I had been repeating something I had not checked carefully enough.

Why third-party testing is stronger: a home test run by the person who made the compound is a self-selected result. The test run by a neutral third party removes obvious sources of bias.

Lateral-flow devices: like a rapid COVID test. They have a reagent strip and produce a colour result. They are quick but not precise and not intended for quantitative work.

What you can use home tests for: confirmation that a solution contains peptide (as opposed to being saline alone), rough screening for very different compounds (semaglutide versus totally unrelated compound). What you cannot use them for: precise purity assessment or verification that the identity is correct.

Coming back to post #5, because the follow-up matters more than the original answer.

Immunoassay limitations: tests that use antibodies have cross-reactivity limitations. An antibody raised to semaglutide will cross-react to some degree with tirzepatide and other structurally similar compounds. The test result conflates them.

Colorimetric tests: colour intensity correlates with concentration, but the relationship is non-linear at extremes and the correlation depends on the exact conditions (pH, temperature, timing). Reading the colour visually introduces subjectivity.

Practical note that does not fit anywhere else. Whatever you conclude from this topic, write down what you did and when. The single most useful thing in your own records is not any individual result; it is that they are dated and consecutive.

Molecular tests: DNA or RNA tests are not applicable to peptides, which do not contain nucleic acids. Peptide-specific tests rely on protein recognition, not nucleic-acid detection.

post #10 answers the question as asked. The question underneath it is different.

False positives and false negatives: no test has 100% sensitivity and 100% specificity. A negative result does not guarantee absence; a positive result does not guarantee presence. The predictive value depends on prevalence.

On post #8 — agreed on the reasoning, with one qualification.

Sample handling matters: if a sample is contaminated or degraded before testing, the test gives you the result for the degraded sample, not for fresh material. That is not a failure of the test; it is the test working correctly.

Enzyme assays: if you have an enzyme that reacts specifically with your compound, an enzyme-based assay can work. These are sometimes available commercially but are less common than antibody-based tests.

Two things before anyone answers the substance.

First, the context in the first post is clear and specific. Second, the question is framed so that an answer can actually address it. Both are the norm here and both matter more than they sound.